Tyrosinemia type 1, also known as fumarylacetoacetate hydrolase deficiency, is a genetic disorder caused by a defect in the homogentisate dioxygenase enzyme (HGO), which is responsible for the degradation of tyrosine. When this enzyme is defective, the tyrosine is not broken down and accumulates in the body, leading to several serious health problems.
The most common symptom of tyrosinemia type 1 is jaundice, which is caused by a buildup of tyrosine in the liver. Other symptoms include poor growth, vomiting, diarrhea, and intellectual disability. Left untreated, this condition can lead to liver failure and kidney damage.
The diagnosis of tyrosinemia type 1 is usually made through a combination of physical examination, family history, and blood tests. Genetic testing can also be used to confirm the diagnosis. Treatment typically consists of a combination of dietary restriction of tyrosine, medications to reduce levels of tyrosine in the blood, and liver transplants in cases of severe liver failure.
With proper treatment, most people with tyrosinemia type 1 can lead healthy, normal lives. However, it is important to be aware of the potential long-term complications associated with this condition, such as kidney damage and liver failure.